



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Beyond the Obstruction: A Case of Lung Cancer with Coincidental COPD Diagnosis

Rosi Maulini^{1*}, Masrul Basyar², Deddy Herman¹, Yessy Susanty Sabri¹

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia

²Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:

COPD

Diagnosis

Lung cancer

Smoking

Spirometry

*Corresponding author:

Rosi Maulini

E-mail address:

rosi.maulini@yahoo.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i4.1236>

ABSTRACT

Background: Lung cancer frequently coexists with chronic obstructive pulmonary disease (COPD), particularly among smokers. The presence of both conditions can complicate diagnosis and lead to poorer outcomes. This case report presents a patient with lung cancer and concurrent COPD, highlighting the diagnostic and management challenges. **Case presentation:** A 60-year-old male presented with a history of smoking, progressive dyspnea, and a recent diagnosis of right lung cancer (T4N3M1c, stage IV B). He also exhibited symptoms suggestive of COPD, such as chronic cough and expectoration. Spirometry confirmed moderate restriction and severe obstruction, consistent with COPD GOLD 3. The patient was managed with both lung cancer treatment and COPD therapy. **Conclusion:** This case underscores the importance of considering COPD in patients with lung cancer, especially those with a history of smoking. Early diagnosis of both conditions is crucial for optimizing treatment strategies and improving patient outcomes.

1. Introduction

Lung cancer and chronic obstructive pulmonary disease (COPD) are two prevalent respiratory diseases that account for a significant proportion of global morbidity and mortality. Lung cancer, characterized by the uncontrolled growth of abnormal cells in the lung tissue, is the leading cause of cancer-related deaths worldwide. COPD, on the other hand, is a progressive lung disease characterized by persistent airflow limitation, primarily caused by chronic inflammation and structural changes in the airways and lung parenchyma. The coexistence of lung cancer and COPD is a well-documented phenomenon, with estimates suggesting that 45-63% of lung cancer

patients worldwide also have COPD. This comorbidity presents significant diagnostic and therapeutic challenges due to the overlapping symptoms and the potential for accelerated disease progression in patients with both conditions. The presence of COPD can complicate the diagnosis and treatment of lung cancer, while lung cancer can exacerbate the symptoms and progression of COPD. This intricate interplay between the two diseases underscores the need for a comprehensive understanding of their shared risk factors, pathophysiological mechanisms, and clinical implications.¹⁻³

Smoking is a common risk factor for both lung cancer and COPD, contributing to chronic

inflammation, oxidative stress, and DNA damage. The chronic inflammation associated with COPD is thought to play a crucial role in the development and progression of lung cancer. Inflammatory cells release reactive oxygen species and other mediators that can damage DNA and promote carcinogenesis. Additionally, the airway remodeling and impaired mucociliary clearance observed in COPD can lead to the accumulation of carcinogens in the lungs, further increasing the risk of lung cancer. In individuals with COPD, the risk of developing lung cancer is significantly elevated compared to those with normal lung function. This increased risk is attributed to the shared risk factors and the potential for COPD to promote carcinogenesis through chronic inflammation and airway remodeling. The presence of COPD can also influence the treatment options and outcomes for lung cancer patients. Patients with both conditions may be less tolerant to aggressive cancer treatments, such as surgery or radiation therapy, due to their compromised lung function. Moreover, COPD can increase the risk of postoperative complications and mortality in lung cancer patients undergoing surgery.⁴⁻⁷

Early diagnosis of both COPD and lung cancer is essential for optimizing treatment strategies and improving patient outcomes. However, the diagnosis of COPD in patients with lung cancer can be challenging due to the overlap in symptoms, such as cough, dyspnea, and reduced exercise capacity. Spirometry, a simple and non-invasive test that measures lung function, is a valuable tool for identifying airflow obstruction and confirming the diagnosis of COPD in these patients.⁸⁻¹⁰ This case report presents a patient with lung cancer and concurrent COPD, emphasizing the importance of a comprehensive evaluation and individualized management plan for patients with both conditions.

2. Case Presentation

This report details the case of a 60-year-old male who presented with a complex clinical picture characterized by the co-occurrence of lung cancer and

chronic obstructive pulmonary disease (COPD). The patient's presentation, diagnostic workup, and subsequent management are outlined below. The patient, a 60-year-old male, presented to the pulmonology clinic with a primary complaint of progressively worsening shortness of breath (dyspnea) over the past six months. This dyspnea was particularly pronounced during physical exertion, limiting his ability to perform daily activities. He reported a chronic cough, productive of white sputum, which had persisted for several years. Additionally, the patient revealed a significant smoking history of 40 pack-years, indicating a long-term exposure to tobacco smoke, a known risk factor for both lung cancer and COPD. Notably, the patient had recently been diagnosed with right lung cancer at an advanced stage (T4N3M1c, stage IVB). This staging indicates a large tumor with involvement of lymph nodes and distant metastasis, signifying a poor prognosis. The patient had not yet commenced any treatment for his lung cancer at the time of presentation to the pulmonology clinic. Physical examination revealed several key findings. The patient appeared to be in respiratory distress, with noticeable difficulty breathing even at rest. Auscultation of the lungs revealed diminished breath sounds throughout both lung fields, suggesting reduced air entry. Furthermore, wheezing, a high-pitched whistling sound produced by airflow through narrowed airways, was also audible, particularly during expiration. These findings are consistent with airflow obstruction, a hallmark characteristic of COPD. The patient's oxygen saturation, measured by pulse oximetry, was found to be lower than normal, indicating hypoxemia. This reduced blood oxygen level further supports the presence of significant respiratory compromise. No other remarkable findings were noted on physical examination. Routine blood tests were performed as part of the patient's initial evaluation. Notably, a complete blood count revealed an elevated white blood cell count, which can be indicative of an underlying inflammatory process or infection. However, further investigation would be required to determine the

specific cause of this elevation. Other blood parameters were within normal limits. A chest X-ray was obtained, which confirmed the presence of a mass in the right lung, consistent with the prior diagnosis of lung cancer. Additionally, the X-ray revealed hyperinflation of the lungs, a common finding in COPD characterized by an abnormal increase in lung volume. To further assess the extent of the lung cancer and evaluate the presence of COPD-related changes, a computed tomography (CT) scan of the chest was performed. The CT scan confirmed the presence of the right lung mass and additionally revealed the presence of emphysema, a form of COPD characterized by destruction of the alveoli, the tiny air sacs in the lungs responsible for gas exchange. The CT findings provided further evidence supporting the coexistence of lung cancer and COPD in this patient. Spirometry, a key diagnostic test for COPD, was performed to objectively assess the patient's lung function. Spirometry measures the volume and flow of air that can be inhaled and exhaled, providing valuable information about lung capacity and airflow limitations. The results of the spirometry demonstrated a significant reduction in both the forced expiratory volume in one second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC). These findings are consistent with a diagnosis of COPD, specifically indicating the presence of severe airflow obstruction, classified as GOLD 3 according to the Global Initiative for chronic obstructive lung disease (GOLD) guidelines. Based on the comprehensive clinical evaluation, including the patient's history, physical examination findings, imaging studies, and pulmonary function testing, a diagnosis of lung cancer with concurrent COPD was established. This dual diagnosis has significant implications for the patient's management and prognosis, as both conditions can contribute to respiratory decline and impact overall survival. The presence of COPD in this patient with advanced lung cancer introduces complexities in treatment planning. COPD can limit the patient's tolerance to aggressive cancer therapies, such as surgery or radiation, due to the potential for further

compromise of lung function. Therefore, a multidisciplinary approach involving pulmonologists and oncologists is crucial to develop an individualized treatment plan that addresses both conditions while optimizing the patient's quality of life (Table 1).

The management of this patient with concurrent lung cancer and COPD required a multifaceted approach, addressing both the oncological needs and the respiratory complications. The treatment strategy was tailored to the patient's specific clinical presentation, disease severity, and overall health status. Given the patient's significant smoking history and its contribution to both lung cancer and COPD, smoking cessation was emphasized as a crucial component of the management plan. The patient received counseling on the detrimental effects of smoking and was provided with resources to aid in quitting, including information on nicotine replacement therapy and behavioral support programs. To improve exercise capacity, enhance quality of life, and optimize respiratory function, the patient was referred to a pulmonary rehabilitation program. This comprehensive program typically involves supervised exercise training, education on disease management, and psychosocial support, all aimed at improving the overall well-being of patients with chronic respiratory conditions. Although the patient presented with dyspnea and hypoxemia, his oxygen saturation was deemed adequate on room air at the time of assessment. Therefore, supplemental oxygen therapy was not immediately indicated. However, the need for oxygen therapy would be reassessed periodically as the patient's condition evolved. The patient's weight loss was addressed through dietary modifications and nutritional counseling. Adequate nutrition is essential for maintaining overall health and supporting the body's ability to cope with chronic diseases. The patient received guidance on appropriate caloric intake, balanced nutrition, and strategies to manage any eating difficulties related to his respiratory conditions. To address the patient's COPD and improve airflow obstruction, a combination of bronchodilator

medications was prescribed. The patient was started on a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) in a single inhaler for maintenance bronchodilation. This combination therapy is commonly used in COPD management to relax airway muscles and improve breathing. In addition to the maintenance bronchodilator, a short-acting beta-agonist (SABA) inhaler was prescribed for as-needed use to relieve breakthrough shortness of breath. This provides the patient with a rescue medication to manage acute exacerbations of dyspnea. Furthermore, acetylcysteine, a mucolytic agent, was prescribed to help thin the patient's secretions and facilitate their clearance from the airways. This can help reduce cough and improve airway patency. Given the advanced stage of the patient's lung cancer, chemotherapy was planned for initiation after discharge. The specific chemotherapy regimen would be determined based on the tumor histology, staging, and the patient's overall health status. A multidisciplinary team involving oncologists and pulmonologists would collaborate to select the most appropriate treatment strategy. To address the patient's cancer-related pain, morphine, an opioid analgesic, was prescribed. Pain management is crucial to improve quality of life and ensure patient comfort. The patient also presented with Superior Vena Cava Syndrome (SVCS), a condition caused by compression of the superior vena cava, a major vein that carries blood from the upper body to the heart. SVCS can lead to facial swelling, shortness of breath, and other symptoms. To manage SVCS, the patient was prescribed furosemide, a diuretic to reduce fluid retention, and methylprednisolone, a corticosteroid to reduce inflammation. Close follow-up was planned to monitor the patient's response to treatment and manage any complications. Regular evaluations of COPD treatment were scheduled every month, including assessments of symptoms, lung function, and medication effectiveness. Repeat spirometry was planned in 6 months to assess changes in lung function and adjust treatment as needed. Unfortunately, despite the comprehensive

management plan, the patient's overall prognosis remained poor due to the advanced stage of his lung cancer. He succumbed to his illness 7 days after discharge, highlighting the severity of this comorbid condition and the challenges in managing patients with advanced lung cancer and COPD (Table 2).

3. Discussion

Diagnosing lung cancer in patients with pre-existing COPD can be particularly challenging due to the overlap in symptomatology. Both conditions often present with symptoms such as chronic cough, dyspnea, and reduced exercise tolerance, making it difficult to distinguish between the two based on clinical presentation alone. In this case, the patient's initial symptoms of progressive dyspnea and chronic cough could have been attributed to either his recently diagnosed lung cancer or underlying COPD, or a combination of both. This highlights the importance of maintaining a high index of suspicion for both conditions in patients with a history of smoking and respiratory symptoms. The use of imaging techniques, such as chest X-rays and computed tomography (CT) scans, is crucial in identifying the presence of lung cancer. However, these imaging modalities may not always be able to definitively diagnose COPD, especially in its early stages. Pulmonary function testing, particularly spirometry, remains the gold standard for diagnosing COPD and assessing the severity of airflow obstruction. In this case, spirometry played a pivotal role in confirming the diagnosis of COPD and classifying its severity according to the Global Initiative for chronic obstructive lung disease (GOLD) guidelines. The clinical presentation of lung cancer and COPD can be remarkably similar, especially in the early stages of these diseases. This overlap in symptoms often leads to diagnostic challenges, as the presence of one condition may mask or mimic the other. This diagnostic dilemma is further complicated by the fact that both diseases frequently co-exist in individuals with shared risk factors, primarily smoking.

Table 1. Anamnesis, clinical findings, laboratory, imaging, and diagnosis.

Category	Subcategory	Specific finding	Detail	
Anamnesis	Demographics	Age	60 years old	
		Gender	Male	
		Occupation	Vegetable vendor	
	Presenting complaint		Increased shortness of breath for 1 month	
	History of present illness	Respiratory		Dyspnea on exertion for 1 year, worsening to dyspnea at rest over the past month
				Productive cough with white, thick sputum for 3 months
				Right-sided chest pain for 1 month
				Enlarged lymph nodes in the right neck for 6 months
				Facial and neck swelling for 1 month
		Constitutional	Decreased appetite and weight loss of 17 kg (24%) over 3 months	
Past medical history		No history of malignancy, tuberculosis, asthma, diabetes mellitus, or hypertension		
Family history		No family history of malignancy, tuberculosis, asthma, diabetes mellitus, or hypertension		
Social history		A smoker since age 15, 32 cigarettes/day, last smoked 20 days ago		
		Occupational exposure to dust and fumes in the market for 20 years		
Clinical findings	Vital signs	Blood pressure	130/82 mmHg	
		Heart rate	82 bpm	
		Respiratory rate	20 breaths/min	
		Temperature	36.8°C	
		Oxygen saturation	98% on room air	
		Pain score	3 on Visual Analog Scale (VAS) with morphine	
	General examination			Facial edema
				Enlarged, non-tender, mobile right submandibular lymph node (5x6x7 cm)
				Enlarged, fixed, hard right supraclavicular lymph node (10x8x12 cm)
				Elevated jugular venous pressure (JVP) 5+2 cmH ₂ O
		Respiratory examination		Chest
			Right hemithorax appears flatter than the left	
			Decreased chest expansion on the right side	
			Decreased tactile fremitus on the right side	
			Dullness to percussion on the right side, resonant on the left	
		Decreased breath sounds in the right middle lung field		
		Expiratory wheezing throughout both lung fields		
Extremities		Upper extremity edema		
		No clubbing		
Laboratory	Complete blood count	Hemoglobin	11.7 g/dL	
		Leukocytes	13,040 /mm ³	
		Hematocrit	36%	
		Platelets	277,000 /mm ³	
	Differential count	Neutrophils	67% (segmented and band)	
		Lymphocytes	23%	
		Monocytes	10%	
		Eosinophils	0%	
	Basophils	0%		
Imaging	Chest X-ray		Right lung mass	
	CT scan of the chest with contrast		Right lung mass enhancement after contrast administration	
Special investigations	Spirometry	Forced Expiratory Volume in 1 second (FEV1)	1120 mL (pre-bronchodilator)	
			1130 mL (post-bronchodilator)	
		Forced Vital Capacity (FVC)	1760 mL (pre-bronchodilator)	
			1740 mL (post-bronchodilator)	
		FEV1/FVC ratio	63% (pre-bronchodilator)	
		65% (post-bronchodilator)		
		Interpretation	Moderate restriction, severe obstruction with negative bronchodilator response	
Bronchoscopy		Total obstructive stenosis of the right upper lobe bronchus		
Diagnosis	Pathology		Adenocarcinoma of the lung	
			Stable COPD GOLD 3, Group B	
			Right lung adenocarcinoma T4N3M1c (multiple colli), Stage IV B	
			Superior Vena Cava Syndrome (SVCS) grade 2	
		Cancer-related pain		

Table 2. Management of case and follow-up.

Category	Subcategory	Specific finding	Detail
Management	Non-pharmacological	Smoking cessation	The patient was counseled on the importance of smoking cessation and provided with resources to aid in quitting.
		Pulmonary rehabilitation	The patient was referred to a pulmonary rehabilitation program to improve exercise capacity and quality of life.
		Oxygen therapy	This is not indicated at this time, as the patient's oxygen saturation was 98% on room air.
		Nutritional support	The patient was advised on dietary modifications to address his weight loss and improve his nutritional status.
	Pharmacological	COPD management	Indacaterol 110 mcg/glycopyrronium 50 mcg Breezhaler. 1 puff once daily for maintenance bronchodilation.
		Fenoterol 100 mcg MDI	As needed for breakthrough shortness of breath.
		Acetylcysteine 200 mg	1 capsule twice daily to help thin secretions.
	Lung cancer management	Chemotherapy	Planned for initiation after discharge.
			A specific regimen is to be determined based on tumor histology and staging.
		Symptom management	Pain management
Superior Vena Cava Syndrome (SVCS) management			Furosemide 40 mg. 1 tablet each morning to reduce fluid retention.
Follow-up		Methylprednisolone 8 mg. 1 tablet twice daily to reduce inflammation.	
		Evaluation of COPD treatment every month.	
		Repeat spirometry in 6 months.	
		Unfortunately, the patient died 7 days after discharge.	

The intertwined nature of these conditions necessitates a comprehensive approach to patient evaluation, considering the possibility of both diagnoses even when one has already been established. A persistent cough is a hallmark symptom of both lung cancer and COPD. While both conditions can present with a chronic cough, there are subtle nuances that can aid in differentiation. In lung cancer, the cough may be dry or productive, with the latter potentially accompanied by hemoptysis (coughing up blood), a more alarming sign. The cough associated with COPD is typically chronic and productive, characterized by white or clear sputum.

However, these distinctions are not absolute, and the presence of a chronic cough in a patient with risk factors for both conditions should prompt further investigation. Shortness of breath, or dyspnea, is another common symptom shared by lung cancer and COPD. Dyspnea in lung cancer can arise from various mechanisms, including airway obstruction by the tumor itself, pleural effusion (fluid accumulation around the lungs), or compromised lung function due to tumor infiltration. In COPD, dyspnea primarily stems from airflow obstruction and reduced lung function caused by chronic airway inflammation and emphysema. The character and progression of

dyspnea can offer clues, with lung cancer-related dyspnea potentially having a more rapid onset or association with specific activities. However, the subjective nature of dyspnea and its multifactorial etiology in both conditions often necessitate objective measures like pulmonary function testing to aid in diagnosis. Patients with both lung cancer and COPD often experience reduced exercise tolerance, a debilitating symptom that significantly impacts their quality of life. This decline in physical capacity stems from the compromised respiratory function inherent to both diseases. In lung cancer, tumor burden, airway obstruction, and pleural effusions can limit lung capacity and gas exchange. In COPD, airflow limitation, hyperinflation, and reduced gas transfer contribute to exercise intolerance. This shared symptom underscores the importance of a thorough evaluation to determine the underlying cause and guide appropriate management strategies. Wheezing, a high-pitched whistling sound produced by airflow through narrowed airways, is more commonly associated with COPD. It arises from bronchoconstriction and airway inflammation characteristic of the disease. However, wheezing can also occur in lung cancer when the tumor obstructs the airway, leading to turbulent airflow. The presence of wheezing, especially in a patient with risk factors for both conditions, should not be solely attributed to COPD and warrants further investigation to rule out malignancy. While chest pain can be a symptom of both lung cancer and COPD, it is more frequently encountered in lung cancer. The pain associated with lung cancer can vary in character and location, ranging from a dull ache to a sharp, stabbing pain. It may be localized to the chest or radiate to the back, shoulder, or arm, depending on the tumor's location and involvement of surrounding structures. In COPD, chest pain is less common and may be related to exacerbations, pulmonary hypertension, or musculoskeletal discomfort. The presence of chest pain, especially in a patient with risk factors for lung cancer, necessitates a careful evaluation to determine its etiology. Imaging techniques, such as chest X-rays

and CT scans, are essential tools in the diagnosis of lung cancer. However, these imaging modalities may not always be able to definitively diagnose COPD, especially in its early stages. The interpretation of imaging findings in patients with suspected lung cancer and COPD requires careful consideration of the clinical context and the potential for both conditions to co-exist. A chest X-ray is often the initial imaging test performed in patients with respiratory symptoms, including those suggestive of lung cancer or COPD. In lung cancer, a chest X-ray may reveal a mass, nodule, or other abnormality in the lung parenchyma, pleura, or mediastinum. In COPD, a chest X-ray may show hyperinflation of the lungs, characterized by increased lung volumes, flattening of the diaphragm, and increased retrosternal air space. However, these findings are not specific for COPD and can be observed in other conditions, such as asthma or aging. Moreover, early-stage COPD may not exhibit significant radiographic abnormalities, potentially leading to missed or delayed diagnosis. A CT scan provides more detailed images of the lungs than a chest X-ray and can help to better characterize lung abnormalities. In lung cancer, a CT scan plays a crucial role in staging the disease, assessing tumor size, location, and extent, and evaluating lymph node involvement and distant metastases. In COPD, a CT scan can reveal emphysema, characterized by the destruction of alveolar walls and enlargement of airspaces, as well as airway wall thickening, bronchiectasis, and other structural changes. However, these CT findings may be subtle or absent in early-stage COPD, highlighting the limitations of imaging in diagnosing this condition. Spirometry is a pulmonary function test that measures the volume and flow of air that can be inhaled and exhaled. It is the gold standard for diagnosing COPD and assessing the severity of airflow obstruction. Spirometry is a simple, non-invasive test that provides objective measurements of lung function, aiding in the differentiation of obstructive and restrictive lung diseases and guiding treatment decisions. In COPD, spirometry typically reveals a reduced forced

expiratory volume in one second (FEV1) and a reduced FEV1/forced vital capacity (FVC) ratio, indicating airflow obstruction. The severity of COPD is classified based on the degree of airflow obstruction, as measured by the post-bronchodilator FEV1, according to the GOLD guidelines. Spirometry also helps to monitor disease progression and response to treatment in COPD patients. In lung cancer, spirometry may be used to assess the impact of the tumor on lung function and to evaluate the patient's suitability for surgery or other treatments that may affect respiratory function. A tumor obstructing a major airway can lead to a significant reduction in FEV1, mimicking obstructive lung disease. Spirometry can also help to identify patients with pre-existing lung function impairment, which may influence treatment decisions and prognosis. In addition to imaging and spirometry, other diagnostic tests may be employed to evaluate patients with suspected lung cancer and COPD. These tests provide complementary information and aid in confirming the diagnosis, characterizing the disease, and guiding treatment decisions. Blood tests may be used to assess the patient's overall health, evaluate for anemia or other systemic manifestations, and rule out other conditions that may be causing respiratory symptoms. While blood tests do not directly diagnose lung cancer or COPD, they can provide valuable information about the patient's general health status and identify potential comorbidities that may influence management. Sputum cytology involves examining a sample of sputum under a microscope to look for cancer cells. This non-invasive test can be helpful in diagnosing lung cancer, particularly in patients with a productive cough. However, the sensitivity of sputum cytology can vary depending on the tumor type and location, and negative results do not definitively rule out malignancy. Bronchoscopy is a procedure that involves inserting a thin, flexible tube with a camera on the end into the airways. This allows the physician to directly visualize the airways, obtain biopsies of suspicious lesions, and collect samples for cytological or microbiological analysis. Bronchoscopy is often

used to diagnose lung cancer and can also be helpful in evaluating airway abnormalities in COPD, such as bronchiectasis or excessive mucus production. Thoracentesis is a procedure that involves inserting a needle into the pleural space to remove fluid. The fluid can then be examined for cancer cells or other abnormalities, such as infection or inflammation. Thoracentesis is often performed in patients with pleural effusion, which can be a manifestation of lung cancer or other conditions.¹¹⁻¹⁴

Lung cancer and COPD often co-exist, creating a complex interplay that can significantly impact patient outcomes. Both diseases share common risk factors, most notably smoking, which contributes to chronic inflammation, oxidative stress, and DNA damage, creating a fertile ground for the development of both conditions. The chronic inflammation associated with COPD is thought to play a crucial role in the development and progression of lung cancer. Inflammatory cells release reactive oxygen species and other mediators that can damage DNA and promote carcinogenesis. Additionally, the airway remodeling and impaired mucociliary clearance observed in COPD can lead to the accumulation of carcinogens in the lungs, further increasing the risk of lung cancer. The presence of COPD can also influence the treatment options and outcomes for lung cancer patients. Patients with both conditions may be less tolerant to aggressive cancer treatments, such as surgery or radiation therapy, due to their compromised lung function. Moreover, COPD can increase the risk of postoperative complications and mortality in lung cancer patients undergoing surgery. Lung cancer and COPD share several risk factors, including smoking, environmental exposures, and genetic predisposition. These shared risk factors contribute to the intertwined pathophysiology of these two diseases, often leading to their co-existence and complex clinical presentations. Understanding these shared etiological factors and the underlying mechanisms is crucial for effective prevention, early diagnosis, and management of both conditions. Smoking is undeniably the most significant risk factor for both lung cancer and COPD,

accounting for the vast majority of cases. The harmful chemicals in cigarette smoke initiate and perpetuate a cascade of inflammatory responses, oxidative stress, and DNA damage in the respiratory system. These processes drive the development of both COPD, with its characteristic airway inflammation and emphysema, and lung cancer, with its uncontrolled cell growth and tumor formation. Smoking cessation remains the cornerstone of preventing and managing both diseases, with significant benefits observed even in individuals with established disease. Beyond smoking, exposure to various environmental pollutants, such as asbestos, radon, and air pollution, further increases the risk of developing both lung cancer and COPD. Asbestos fibers, when inhaled, can cause chronic inflammation and fibrosis in the lungs, leading to asbestosis, a risk factor for both diseases. Radon, a naturally occurring radioactive gas, is another significant environmental risk factor, particularly for lung cancer. Air pollution, with its complex mixture of particulate matter and noxious gases, contributes to both airway inflammation and lung carcinogenesis. Minimizing exposure to these environmental hazards is crucial for reducing the risk of both conditions. While environmental factors play a dominant role, genetic susceptibility also contributes to the development of both lung cancer and COPD. Certain genetic variations can increase an individual's vulnerability to these diseases, particularly in the presence of environmental risk factors like smoking. For instance, genetic variations affecting the function of tumor suppressor genes or DNA repair mechanisms can increase the risk of lung cancer. Similarly, genetic variations influencing inflammatory responses or antioxidant defenses can contribute to the development of COPD. Understanding the interplay between genetic and environmental factors is crucial for identifying individuals at higher risk and implementing personalized prevention strategies. Chronic inflammation is a central pathophysiological process underlying both COPD and lung cancer. In COPD, chronic inflammation is primarily triggered by the inhalation of noxious particles and gases,

predominantly cigarette smoke. This chronic irritant exposure sets off a complex inflammatory cascade, involving the recruitment and activation of various immune cells, including neutrophils, macrophages, and lymphocytes, to the airways and lungs. These inflammatory cells release a plethora of mediators, including reactive oxygen species, cytokines, and chemokines, which inflict damage on the airways and lung parenchyma, leading to the characteristic features of COPD, such as airflow obstruction, emphysema, and chronic bronchitis. Chronic inflammation also plays a pivotal role in the development and progression of lung cancer. The inflammatory mediators released by immune cells can directly damage DNA, promoting mutations and genomic instability that can initiate carcinogenesis. Furthermore, chronic inflammation creates a microenvironment conducive to tumor growth and metastasis, providing growth factors, angiogenesis-promoting factors, and immune-suppressive signals that favor tumor development and spread. Targeting chronic inflammation represents a promising avenue for preventing and treating both COPD and lung cancer. Airway remodeling is a hallmark of COPD, characterized by structural changes in the airways that further compromise lung function and increase susceptibility to infections and other complications. These structural alterations include thickening of the airway walls, increased mucus production, and loss of cilia, the tiny hair-like structures that line the airways and help to clear inhaled particles and pathogens. These changes in airway architecture lead to impaired mucociliary clearance, a critical defense mechanism of the respiratory system. Mucociliary clearance relies on the coordinated action of mucus production and ciliary beating to trap and remove inhaled particles, preventing them from reaching the delicate lung tissue. In COPD, the increased mucus production and loss of cilia disrupt this process, allowing inhaled irritants and carcinogens to accumulate in the lungs. This impaired mucociliary clearance can contribute to the development of lung cancer by increasing the residence time of carcinogens in the respiratory tract,

thereby increasing the likelihood of DNA damage and malignant transformation. Moreover, the airway remodeling itself can create a microenvironment that favors tumor growth and metastasis, providing a scaffold for tumor cells to adhere to and proliferate. The presence of COPD can significantly influence the treatment options and outcomes for lung cancer patients. COPD can limit the patient's ability to tolerate aggressive cancer treatments, such as surgery or radiation therapy, due to their compromised lung function. This necessitates careful consideration of the risks and benefits of each treatment modality, often requiring a multidisciplinary approach to optimize treatment strategies and minimize complications. Surgery for lung cancer, while potentially curative, can be particularly challenging in patients with COPD. These patients are at increased risk of postoperative pulmonary complications, such as pneumonia, respiratory failure, and prolonged mechanical ventilation. COPD can impair the lungs' ability to recover from the stress of surgery, leading to increased morbidity and mortality. Careful patient selection, preoperative optimization of lung function, and meticulous postoperative care are crucial for minimizing risks in this population. Radiation therapy, another mainstay of lung cancer treatment, can also pose challenges in patients with COPD. These patients are at increased risk of radiation pneumonitis, an inflammatory reaction in the lungs caused by radiation exposure. Radiation pneumonitis can lead to respiratory symptoms, such as cough, shortness of breath, and chest pain, and in severe cases, can progress to respiratory failure. Careful treatment planning and monitoring are essential to mitigate the risk of radiation pneumonitis in COPD patients. Chemotherapy, often used in conjunction with surgery or radiation therapy, can also be more difficult to tolerate in patients with COPD. These patients may experience more severe side effects, such as fatigue, nausea, and vomiting, which can further compromise their quality of life. Additionally, chemotherapy can exacerbate pre-existing lung function impairment in COPD patients, leading to

increased dyspnea and reduced exercise tolerance. Close monitoring of lung function and supportive care are essential for managing chemotherapy-related side effects in this population.¹⁵⁻¹⁷

Managing patients with co-existing lung cancer and COPD requires a multifaceted and individualized approach, recognizing the complex interplay between these two diseases and their combined impact on patients' respiratory health and overall well-being. The treatment strategy should be tailored to each patient's unique clinical presentation, disease severity, and overall health status, with the goal of optimizing both cancer treatment outcomes and COPD management while preserving quality of life. This often necessitates a multidisciplinary approach, involving pulmonologists, oncologists, respiratory therapists, nurses, and other healthcare professionals, working collaboratively to provide comprehensive and coordinated care. Smoking cessation is of paramount importance in managing both lung cancer and COPD, as smoking is the primary risk factor for both conditions. Continued smoking exacerbates both diseases, accelerating lung function decline in COPD and increasing the risk of cancer recurrence and mortality. All patients with co-existing lung cancer and COPD who smoke should be offered comprehensive smoking cessation support, including counseling, nicotine replacement therapy, and behavioral support programs. Smoking cessation counseling can help patients to identify triggers for smoking, develop coping mechanisms, and build a personalized quit plan. Nicotine replacement therapy, available in various forms such as patches, gum, and lozenges, can help to alleviate withdrawal symptoms and improve the chances of quitting successfully. Behavioral support programs provide additional support and motivation, helping patients to stay on track with their quit plan and overcome challenges. Pulmonary rehabilitation is a crucial component of managing COPD and improving exercise capacity, quality of life, and respiratory function in patients with co-existing lung cancer and COPD. Pulmonary rehabilitation programs typically involve supervised

exercise training, education on disease management, and psychosocial support, all tailored to the individual needs of the patient. Supervised exercise training helps to improve muscle strength and endurance, reduce dyspnea, and enhance exercise tolerance. Education on disease management empowers patients to take an active role in their care, providing them with the knowledge and skills to manage their symptoms, prevent exacerbations, and improve their overall health. Psychosocial support helps patients to cope with the emotional and social challenges of living with chronic respiratory diseases. Pharmacological management of COPD in patients with co-existing lung cancer aims to alleviate symptoms, improve lung function, and prevent exacerbations. The choice of medications depends on the severity of COPD and the presence of other comorbidities. Bronchodilators are the mainstay of COPD treatment, relaxing airway smooth muscle and improving airflow. Long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) are commonly used as maintenance therapy, providing sustained bronchodilation throughout the day. Short-acting beta-agonists (SABAs) are used as rescue medication for rapid relief of breakthrough shortness of breath. Inhaled corticosteroids (ICS) may be added to bronchodilator therapy in patients with frequent exacerbations or persistent symptoms despite bronchodilator use. ICS help to reduce airway inflammation, but their long-term use in COPD patients with co-existing lung cancer requires careful consideration due to potential side effects, such as increased risk of pneumonia and osteoporosis. Other medications that may be used in the management of COPD include mucolytics, such as acetylcysteine, to help thin and clear mucus secretions, and phosphodiesterase-4 inhibitors, such as roflumilast, to reduce inflammation and exacerbations. Treatment of lung cancer in patients with co-existing COPD requires careful consideration of the stage of the disease, the patient's overall health status, and the potential impact of cancer treatment on lung function. The presence of COPD may limit the patient's tolerance to aggressive cancer treatments,

such as surgery or radiation therapy. Surgery is often the preferred treatment for early-stage lung cancer, but it may not be suitable for all patients with COPD. Patients with severe COPD or poor lung function may be at increased risk of postoperative complications, such as pneumonia, respiratory failure, and prolonged mechanical ventilation. Careful patient selection and preoperative optimization of lung function are crucial for minimizing risks. Radiation therapy can be an effective treatment for lung cancer, but it can also cause lung damage, particularly in patients with pre-existing COPD. Radiation pneumonitis, an inflammatory reaction in the lungs, is a potential complication of radiation therapy that can lead to respiratory symptoms and lung function decline. Careful treatment planning and monitoring are essential for minimizing the risk of radiation pneumonitis in COPD patients. Chemotherapy can be used to treat lung cancer, but it can also cause side effects that may be more difficult to tolerate in patients with COPD. These side effects can include fatigue, nausea, vomiting, and decreased blood counts, which can further compromise respiratory function and overall health. Close monitoring and supportive care are essential for managing chemotherapy-related side effects in COPD patients. Targeted therapy and immunotherapy are newer cancer treatments that have shown promise in the treatment of lung cancer. These therapies target specific molecules involved in cancer growth and progression, and they may be better tolerated than traditional chemotherapy in patients with COPD. However, targeted therapy and immunotherapy can also cause side effects, and their use in patients with COPD requires careful monitoring.¹⁸⁻²⁰

4. Conclusion

This case report describes the intricate interplay between lung cancer and COPD, underscoring the crucial importance of early diagnosis and a multifaceted approach to management. The presence of COPD significantly complicates the treatment of lung cancer, while lung cancer can accelerate the

progression of COPD, creating a vicious cycle that demands careful consideration. The case highlights the diagnostic challenges posed by the overlapping symptoms of both conditions, emphasizing the need for a comprehensive evaluation that includes imaging, pulmonary function testing, and careful clinical assessment. Spirometry played a pivotal role in confirming the diagnosis of COPD and classifying its severity, demonstrating its value in differentiating obstructive and restrictive lung diseases. Furthermore, the case underscores the need for an individualized management plan that addresses both the oncological and respiratory aspects of the patient's condition. Smoking cessation, pulmonary rehabilitation, and pharmacological management of COPD are essential components of this comprehensive approach, aiming to alleviate symptoms, improve lung function, and preserve quality of life. The management of lung cancer in patients with co-existing COPD requires careful consideration of the stage of the disease, the patient's overall health status, and the potential impact of cancer treatment on lung function. The presence of COPD may limit the patient's tolerance to aggressive cancer treatments, necessitating a multidisciplinary approach to optimize treatment strategies and minimize complications. In conclusion, this case report serves as a reminder of the complex challenges encountered in managing patients with co-existing lung cancer and COPD. Early diagnosis, smoking cessation, pulmonary rehabilitation, and a multifaceted approach to treatment are vital for improving patient outcomes and preserving quality of life.

5. References

1. Wang R. Some valuable issues regarding the surgery for lung cancer combined with COPD and the postoperative recurrence risk. *Zhongguo Fei Ai Za Zhi*. 2018; 21(3): 221–2.
2. Lee YM, Kim SJ, Lee JH, Ha E. Inhaled corticosteroids in COPD and the risk of lung cancer. *Int J Cancer*. 2018; 143(9): 2311–8.
3. Demiri S, Lorut C, Rabbat A, Luu van Lang D, Lefebvre A, Regnard J-F, et al. Postoperative outcomes of frequent exacerbator patients with chronic obstructive pulmonary disease after resection of non-small cells lung cancer. *COPD*. 2018; 15(4): 361–8.
4. Telephone follow-up to identify incident lung cancer symptoms in COPD patients. *Br J Cancer Res*. 2019; 2(4).
5. Lin YP, Docherty C, Burke E, Woodhouse L, Patel ARC. The impact of COPD on lung cancer treatment and survival. *Lung Cancer*. 2019; 127: S27.
6. Li X, Li S, Yan S, Wang Y, Wang X, Sihoe ADL, et al. Impact of preoperative exercise therapy on surgical outcomes in lung cancer patients with or without COPD: a systematic review and meta-analysis. *Cancer Manag Res*. 2019; 11: 1765–77.
7. Lusk CM, Wenzlaff AS, Watza D, Sieren JC, Robinette N, Walworth G, et al. Quantitative imaging markers of lung function in a smoking population distinguish COPD subgroups with differential lung cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2019; 28(4): 724–30.
8. Coote J, Tang C, Salem A, Bayman N, Chan C, Cobben D, et al. Outcomes of curative-intent radiotherapy in patients with severe COPD or lung fibrosis. *Lung Cancer*. 2020; 139: S32.
9. Nagasaka M, Lehman A, Chlebowski R, Haynes BM, Ho G, Patel M, et al. COPD and lung cancer incidence in the women's health initiative observational study: a brief report. *Lung Cancer*. 2020; 141: 78–81.
10. Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: Findings from the Fukuoka tobacco-related lung

- disease (FOLD) registry. *Asian Pac J Cancer Prev.* 2020; 21(3): 667–73.
11. Tang J, Ramis-Cabrer D, Curull V, Wang X, Qin L, Mateu-Jiménez M, et al. Immune cell subtypes and cytokines in lung tumor microenvironment: Influence of COPD. *Cancers (Basel).* 2020; 12(5): 1217.
 12. Tessema M, Tassew DD, Yingling CM, Do K, Picchi MA, Wu G, et al. Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients. *Lung Cancer.* 2020; 146: 189–96.
 13. Watza D, Lusk CM, Dyson G, Purrington KS, Wenzlaff AS, Neslund-Dudas C, et al. COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk. *Int J Cancer.* 2020; 147(3): 747–56.
 14. Uliński R, Kwiecień I, Domagała-Kulawik J. Lung cancer in the course of COPD-emerging problems today. *Cancers (Basel).* 2022; 14(15): 3819.
 15. Behr CM, Koffijberg H, IJzerman MJ, Kauczor H-U, Revel M-P, Silva M, et al. EP01.02-001 citizens' perspective on combination screening for lung cancer, COPD and CVD. *J Thorac Oncol.* 2022; 17(9): S165–6.
 16. Salvato I, Ricciardi L, Nucera F, Nigro A, Dal Col J, Monaco F, et al. RNA-binding proteins as a molecular link between COPD and lung cancer. *COPD.* 2023; 20(1): 18–30.
 17. Lu J, Shi Y, Zhang F, Zhang Y, Zhao X, Zheng H, et al. Mechanism of lncRNA-ICL involved in lung cancer development in COPD patients through modulating microRNA-19-3p/NKRF/NF- κ B axis. *Cancer Cell Int.* 2023; 23(1): 58.
 18. Nielsen N, Ballinger Z, Muñoz Villarreal B, Kovell L, Ito Fukunaga M, Castañeda-Avila M. Estimating the impact of asthma and COPD on lung cancer screening in the USA. *Lung.* 2024; 203(1): 2.
 19. Riordino S, Rosenfeld R, Formica V, Morelli C, Parisi G, Torino F, et al. Effectiveness of immunotherapy in non-small cell lung cancer patients with a diagnosis of COPD: Is this a hidden prognosticator for survival and a risk factor for immune-related adverse events? *Cancers (Basel).* 2024; 16(7).
 20. Zhang D, Liu H, Zhao F, Guo P, Li J, Lu T, et al. Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration. *BMC Cancer.* 2024; 24(1): 453.